Log in to save to my catalogue

Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic bre...

Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic bre...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e43bea5e36154033b3975c0ba6d40d38

Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer

About this item

Full title

Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer

Publisher

England: BioMed Central Ltd

Journal title

Genome medicine, 2023-07, Vol.15 (1), p.55-55, Article 55

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Cyclin-dependent kinase 4/6 inhibitor (CDK4/6) therapy plus endocrine therapy (ET) is an effective treatment for patients with hormone receptor-positive/human epidermal receptor 2-negative metastatic breast cancer (HR+/HER2- MBC); however, resistance is common and poorly understood. A comprehensive genomic and transcriptomic analysis of pretreatmen...

Alternative Titles

Full title

Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_e43bea5e36154033b3975c0ba6d40d38

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e43bea5e36154033b3975c0ba6d40d38

Other Identifiers

ISSN

1756-994X

E-ISSN

1756-994X

DOI

10.1186/s13073-023-01201-7

How to access this item